PT - JOURNAL ARTICLE AU - Chia-Hung Kao AU - Jih-Fang Hsieh AU - Shih-Chuan Tsai AU - Yung-Jen Ho AU - Sheng-Ping ChangLai AU - Jong-Kang Lee TI - Paclitaxel-Based Chemotherapy for Non–Small Cell Lung Cancer: Predicting the Response with <sup>99m</sup>Tc-Tetrofosmin Chest Imaging DP - 2001 Jan 01 TA - Journal of Nuclear Medicine PG - 17--20 VI - 42 IP - 1 4099 - http://jnm.snmjournals.org/content/42/1/17.short 4100 - http://jnm.snmjournals.org/content/42/1/17.full SO - J Nucl Med2001 Jan 01; 42 AB - The purpose of this study was to retrospectively predict the chemotherapeutic response to paclitaxel for non–small cell lung cancer (NSCLC) using 99mTc-tetrofosmin (TF) uptake and to detect the expression of 170-kDa multidrug resistance–mediated P-glycoprotein (MDR-Pgp). Methods: Before chemotherapy with paclitaxel, 20 patients with stage IIIb or IV NSCLC were enrolled in this study to undergo early and delayed 99mTc-TF chest imaging for calculating tumor-to-normal lung ratios (T/NL) and retention indices (RI) for assessment of the MDR-Pgp in NSCLC. Results: The early and delayed mean T/NLs were 1.59 ± 0.25 and 1.50 ± 0.25, respectively, for 10 patients with a good response and 1.09 ± 0.09 and 1.03 ± 0.05, respectively, for 10 patients with a poor response. The differences were shown to be significant (P &lt; 0.001) by independent Student t tests. However, no significant differences (P = 0.801) between good-response patients (−5.70% ± 3.67%) and poor-response patients (−5.23% ± 4.51%) were found in RI. In addition, other prognostic factors (age, sex, tumor size, stage, and cell type) were not significantly different between good-response patients and poor-response patients. Conclusion: 99mTc-TF chest images are potential tools for understanding MDR-Pgp expression in NSCLC and for predicting the chemotherapeutic response to paclitaxel.